Who
Robert C. Goeltz II
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Arcus Biosciences; Chief Financial Officer, Unity Biotechnology; Chief Financial Officer, CytomX Therapeutics.
In numbers
- Trades disclosed
- 71
- Buys
- 1
- Sells
- 13
- Bought
- $108K
- Sold
- $1.9M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 21 Jan 2016
- Last trade
- 11 May 2026
- Last filed
- 12 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 May 2026filed 12 May 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $199K7,763 at $25.63 | filing |
| 11 May 2026filed 12 May 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $199K7,763 at $25.63 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,000 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,000 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 31 Dec 2025filed 2 Jan 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $153K6,552 at $23.38 | filing |
| 31 Dec 2025filed 2 Jan 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $153K6,552 at $23.38 | filing |
| 17 Dec 2025filed 18 Dec 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $132K5,960 at $22.16 | filing |
| 16 Dec 2025filed 18 Dec 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $147K6,702 at $21.88 | filing |
| 26 Nov 2025filed 26 Nov 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $125K5,000 at $25.00 | filing |
| 28 Oct 2025filed 29 Oct 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $100K5,000 at $20.00 | filing |
| 23 Jan 2025filed 27 Jan 2025 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 23 Jan 2025filed 27 Jan 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 31 Dec 2024filed 3 Jan 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $54K3,594 at $15.00 | filing |
| 15 Dec 2024filed 17 Dec 2024 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code F | $162K10,099 at $16.08 | filing |
| 23 Jan 2024filed 23 Feb 2024 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 23 Jan 2024filed 25 Jan 2024 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —86,600 at $0.00 | filing |
| 23 Jan 2024filed 25 Jan 2024 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —21,300 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $40K2,004 at $20.00 | filing |
News
Arcus Biosciences Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer DataRCUS · investors.com · 20 Oct 2026Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical ContrastRCUS · themarketsdaily.com · 19 Oct 2026Valion Bio, Inc. Common Stock (NASDAQ:VBIO) vs. Arcus Biosciences (NYSE:RCUS) Head-To-Head ComparisonRCUS · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Robert C. Goeltz II; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.